ANI Pharmaceuticals Receives FDA Approval for Generic Isosorbide Mononitrate Tablets
核心洞察
ANI Pharmaceuticals received FDA approval for its Abbreviated New Drug Application and launched generic Isosorbide Mononitrate Tablet USP in 10 mg and 20 mg strengths.
The generic product serves as an alternative to the reference listed drug Monoket® and represents a limited-competition product opportunity.
CEO Nikhil Lalwani emphasized the launch reinforces ANI's R&D capabilities and commitment to maintaining a steady cadence of new product launches.
ANI Pharmaceuticals, Inc. announced that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) and launched Isosorbide Mononitrate Tablet USP in 10 mg and 20 mg strengths. The generic product serves as an alternative to the reference listed drug Monoket®, marking another addition to ANI's portfolio of limited-competition generic medications.
Strategic Market Entry
"We are pleased to announce FDA approval and launch of Isosorbide Mononitrate Tablet USP, which highlights our efforts to bring limited-competition products to market and ensure that our high-quality products are readily accessible to our customers and patients in need," stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
The launch represents ANI's continued focus on identifying and developing generic alternatives in therapeutic areas with limited competition, potentially providing cost-effective treatment options for patients requiring nitrate therapy.
Company Portfolio Expansion
Lalwani emphasized that "this launch reinforces the strength of our R&D capabilities and operational execution as well as our commitment to maintaining a steady cadence of new product launches." The approval demonstrates ANI's ability to successfully navigate the ANDA process and bring generic products to market through its established regulatory and manufacturing capabilities.
ANI Pharmaceuticals operates as a diversified biopharmaceutical company with three main business segments: Rare Disease, Generics, and Brands. The company's Generics business leverages R&D expertise, operational excellence, and U.S.-based manufacturing to develop and commercialize generic alternatives to branded pharmaceuticals.
Therapeutic Applications
Isosorbide mononitrate belongs to the nitrate class of medications and is commonly prescribed for cardiovascular conditions. The availability of a generic alternative may provide healthcare providers and patients with additional treatment options while potentially reducing medication costs.
The company's mission centers on "Serving Patients, Improving Lives" through developing, manufacturing, and commercializing innovative and high-quality therapeutics across multiple therapeutic areas including ophthalmology, rheumatology, nephrology, neurology, and pulmonology.